Localization of Functional Prostaglandin E2 Receptors EP3 and EP4 in the Nuclear Envelope*

Mousumi BhattacharyaDagger §, Krishna Peri, Alfredo Ribeiro-da-SilvaDagger , Guillermina AlmazanDagger , Hitoshi Shichiparallel , Xin Hou, Daya R. VarmaDagger , and Sylvain Chemtob**Dagger Dagger

From the Dagger  Department of Pharmacology & Therapeutics, McGill University, Montreal, PQ, Canada, H3G 1Y6, the ** Departments of Pediatrics, Ophthalmology and Pharmacology, and the  Research Center of Hôpital Ste. Justine, University of Montreal, Montreal, PQ, Canada H3T 1C5, and the parallel  Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan 48201

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The effects of prostaglandin E2 are thought to be mediated via G protein-coupled plasma membrane receptors, termed EP. However recent data implied that prostanoids may also act intracellularly. We investigated if the ubiquitous EP3 and the EP4 receptors are localized in nuclear membranes. Radioligand binding studies on isolated nuclear membrane fractions of neonatal porcine brain and adult rat liver revealed the presence of EP3 and EP4. A perinuclear localization of EP3alpha and EP4 receptors was visualized by indirect immunocytofluorescence and confocal microscopy in porcine cerebral microvascular endothelial cells and in transfected HEK 293 cells that stably overexpress these receptors. Immunoelectron microscopy clearly revealed EP3alpha and EP4 receptors localization in the nuclear envelope of endothelial cells; this is the first demonstration of the nuclear localization of these receptors. Data also reveal that nuclear EP receptors are functional as they affect transcription of genes such as inducible nitric-oxide synthase and intranuclear calcium transients; this appears to involve pertussis toxin-sensitive G proteins. These results define a possible molecular mechanism of action of nuclear EP3 receptors.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Prostaglandin E2 (PGE2)1 is one of the most abundant prostanoids in the brain (1) and plays an important role in many cerebral functions, particularly in the newborn (2). PGE2 also influences mitogenesis (3), promotes growth and metastasis of tumors (4), and stimulates gene transcription (5). To date, the biological actions of PGE2 have been attributed to result from its interaction with plasma membrane G protein-coupled receptors termed EP, which include EP1, EP2, EP3, and EP4 subtypes (6). Recent studies have shown that the nuclear membrane contains high levels of cyclooxygenase-1 and -2 and of PGE2 (7). Possible intracellular sites of action for prostanoids are also suggested by other data. For example, a transporter that mediates the influx of prostanoid has been identified (8). Cytosolic phospholipase A2 undergoes a calcium-dependent translocation to the nuclear envelope (9), and cyclooxygenase-2 has been shown to translocate to the nucleus in response to certain growth factors (10). It is thus possible that prostanoids may exert some of their effects via intracellular EP receptors, to have a direct nuclear action as recently proposed by Goetzl et al. (11), and Morita et al. (12).

It has generally been assumed that the signal transduction cascades are initiated at the plasma membrane and not the nuclear membranes. However, recent studies have disclosed that the nuclear envelope plays a major role in signal transduction cascades (13, 14). In fact, a novel nuclear lipid metabolism that is a part of unique nuclear signaling cascade termed NEST (nuclear envelope signal transduction) has been hypothesized (15). Both heterotrimeric and low molecular weight G proteins (15, 16), phospholipase C (13), phospholipase D (15), and adenylate cyclase (17) have shown to be localized at the nucleus. The nuclear membranes also have distinct inositide cycles (18) and receptors for 1,4,5-triphosphate and inositol 1,3,4,5-tetrakisphosphate (13). Altogether these data raise the possibility of the presence of nuclear prostanoid receptors. This inference has recently been suggested for EP1 (19), but whether or not this single observation is specific for this receptor or applies to other prostanoid receptors, especially of the widely distributed EP3 and EP4 subtypes, is unknown.

In the present study, we investigated the possible expression of nuclear EP3 and EP4 receptors using human embryonic kidney (HEK) 293 cells, porcine microvascular endothelial cells, newborn pig brain, and adult rat liver. We selected these tissues because many high affinity PGE2 binding sites have been reported in the plasma membranes of pig brain (20) and rat liver (21). We focused on EP3 receptors that are most ubiquitous of the four EP subtypes (6) and also examined localization of EP4 receptors. Our data provide novel evidence for the existence of EP3 and EP4 receptors in the nuclear envelope and reveal that these receptors are functional, and their actions appear to involve pertussis toxin (PTX)-sensitive G proteins.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- AH23848B was a gift from Glaxo-Wellcome, UK and M&B 28,767 from Rhone-Poulenc Rorer, UK. The following products were purchased: PGE2, 17-phenyl trinor PGE2 (Cayman Chemicals, Ann Arbor, MI); Dulbecco's modified Eagle's medium, Geneticin (Life Technologies, Inc., Burlington, ON); [3H]PGE2 (182 Ci/mmol), 45Ca2+ (2 mCi/49.5 µg of Ca), and [alpha -32P] (3000 Ci/mmol) (Amersham Pharmacia Biotech, Mississauga, ON); all other chemicals were from Sigma.

Animals-- Newborn pigs (1-3 days old) were killed with intracardiac pentobarbital under halothane anesthesia, and tissues of interest were removed. Adult Sprague-Dawley male rats (250-300 g) were decapitated and had livers removed.

Cell Culture-- HEK 293 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum. Primary cultures of porcine cerebral endothelial cells from brain microvessels (20) were established as described previously (22).

Preparation of Subcellular Fractions-- All steps were performed at 4 °C using solutions containing 1.1 mM acetylsalicylic acid, 1 mM benzamidine, 0.2 mM phenylmethylsulfonyl fluoride and 100 µg/ml soybean trypsin inhibitor. Nuclei were isolated from adult rat liver (23) and newborn porcine brain cortex (24). Endoplasmic reticulum (ER) was isolated as described (25). The purity of cellular fractions was ascertained by determining 5'-nucleotidase using a Sigma diagnostic kit as a marker for plasma membrane (23), and glucose-6-phosphatase was assayed as a marker for ER (26). Proteins were determined by the Bio-Rad assay. 5'-Nucleotidase activity (units/mg protein) was 240 ± 15.4 and 5.3 ± 1.3 in plasma and nuclear membrane fractions, respectively, suggesting that the nuclear membranes were relatively free of contamination by plasma membranes. Glucose-6-phosphatase (an ER marker) specific activity (mmol PO4 released/mg of protein) was 25.2 ± 2.3 in ER and 22.8 ± 3.1 in nuclear membrane fractions since the outer nuclear membrane is contiguous with the ER (27).

Radioligand Binding-- Saturation isotherms of specific binding of [3H]PGE2 to membrane fractions from newborn porcine brain cortex and displacement of [3H]PGE2 by receptor isoform-specific ligands on brain cortex and rat liver was performed essentially as previously reported (20). Receptor densities (Bmax) and affinity constants (KD) were determined using Prism Graphpad program (San Diego, CA).

Immunoblotting of EP Receptors-- Western blotting of EP3alpha and EP4 receptors was conducted as described (28) on newborn brain nuclear and plasma membrane fractions. After immunoblotting using EP3alpha - or EP4-specific polyclonal rabbit antibodies (29) (1:1000), immunoreactive bands were visualized by chemiluminescence (Amersham Pharmacia Biotech) as per manufacturer instructions.

EP3 and EP4 Receptor Expression in HEK 293 Cells-- The full-length cDNA fragments corresponding to human EP3alpha (30) and EP4 (31) were cloned separately into the mammalian expression vector pRC-CMV (Invitrogen). HEK 293 cells (2 × 105) were transfected with 2 µg of plasmid DNA and 8 µl of LipofectAMINE in Opti-MEM (Life Technologies, Inc.) according to the manufacturer instructions; Geneticin (1 mg/ml) -resistant clones were selected and maintained in Dulbecco's modified Eagle's medium medium containing Geneticin (0.2 mg/ml).

Immunocytochemical Detection of EP Receptors-- The immunolocalization of EP receptors in HEK 293 and porcine cerebrovascular endothelial cells was performed by indirect immunofluorescence (32). Briefly, cells were washed in phosphate-buffered saline (PBS), fixed in acetone-methanol (1:1) for 10 min at -20 °C and incubated for 1 h with specific rabbit anti-EP3alpha or anti-EP4 receptor antibodies (29) diluted 1:50 in PBS containing 5% goat serum, 5% fetal calf serum, and 0.1% Triton X-100. After washing, samples were incubated for 1 h with Texas Red-conjugated IgG (BioCan, Mississauga, ON) diluted 1:50 in the above buffer. To detect plasma membrane immunolocalization, permeabilization of cells with 0.1% Triton X-100 was limited to 15 min (to improve preservation of membranes) before incubation with primary antibodies and subsequent steps. As a negative control, either the primary antibody was omitted or primary antibody with its cognate peptide (29) was added. Intracellular membranes (predominantly ER) were stained using 3,3'-dihexyloxacarbocyanine iodide (DiOC6 (3)) and nuclei were stained with DAPI, or Sytox Green according to the instructions of the manufacturer (Molecular Probes, Eugene, OR).

Immunoelectron Microscopy of EP Receptors-- Pre-embedding immunogold staining was done as described in detail previously (33, 34). Porcine brain endothelial cells were fixed for 30 min at room temperature in 4% paraformaldehyde and 0.25% glutaraldehyde in 0.1 M phosphate buffer, washed with 0.2% Triton X-100 in PBS for 15 min at room temperature, and incubated with anti-EP3alpha or anti-EP4 receptor antibodies (1:10) overnight at 4 °C in PBS; this limited permeabilization of cells is required for pre-embedding immunoelectron microscopy for adequate ultrastructural preservation. The immunogold reaction (33) was performed overnight at 4 °C with goat anti-rabbit IgG coupled to 1 nm of gold (1:50) (Amersham Pharmacia Biotech), the reaction was intensified using an Intense Silver Enhancement kit (Amersham Pharmacia Biotech) according to the instructions of the manufacturer. After osmification in 1% osmium tetroxide and Epon embedding, ultrathin sections were observed using a transmission electron microscope (Philips 410 LS, Netherlands).

RNA Hybridization Studies-- Nuclei were isolated from endothelial cells (35), and aliquots (100 µg of protein) were incubated in the presence or absence of 0.1 µM EP3 agonist, M&B 28,767, for 60 min at 37 °C in a total volume of 40 µl (per reaction tube) of 10 mM Tris-HCl buffer (pH 8.0) containing 5 mM MgCl2, 300 mM KCl, 0.5 mM each of ATP, CTP, GTP, and UTP, RNase guard (111 units), and DNase (10 units). RNA was extracted as described previously (28). For the isolation of total cytoplasmic RNA, cells were incubated in the presence or absence of test agents for 1 h and washed with ice-cold PBS. Nuclear and total RNA were applied to a nylon membrane using a vacuum filtration apparatus (36). 32P-Labeled cDNA probes for porcine iNOS (37) and mouse beta -actin (Ambion) were prepared using an oligolabeling kit (Amersham Pharmacia Biotech); unincorporated nucleotides were removed by G-25 column chromatography. Membranes were hybridized to the radiolabeled probes and washed (36). The bands were visualized and quantified by Phosphorimaging (Molecular Dynamics).

Nuclear Calcium Signals and Uptake-- The uptake of 45Ca2+ in isolated nuclei was determined as described previously (14). Briefly, nuclei were resuspended in buffer A (125 mM KCl, 2 mM K2HPO4, 25 mM Hepes, 4 mM MgCl2, and 400 nM CaCl2, pH 7.0). 45Ca2+ (2 µCi/ml) was added, and samples were incubated in the presence or absence of test agents at 37 °C for different time periods. The reaction was terminated with ice-cold buffer containing 50 mM Tris-HCl and 150 mM KCl (pH 7.0), filtered under vacuum on glass fiber filters (GF/B, Whatman). The radioactivity on filters was counted on a beta-counter (Beckman LS 7500). The 45Ca2+ transient was defined as the radioactivity at a given time minus the radioactivity at time zero.

Effects of test agents on calcium transients were measured by fura-2/AM fluorometry as described (14, 22) with some modifications. Isolated liver nuclei were resuspended in buffer A and preloaded with 7.5 µM fura-2/AM for 45 min at 4 °C. The nuclei were washed and stimulated (~2 × 106 nuclei/ml) with various test agents. The intranuclear calcium concentration was measured with a spectrofluorometer (LS 50, Perkin Elmer, Beaconsfield, UK) and fluorescent signal calibrated (22).

To assess the role of PTX-sensitive G proteins in nuclear Ca2+ transients, isolated rat liver nuclei were treated with PTX as described (38). Prior to treatment, the toxin was preactivated by incubating at 37 °C for 10 min in 50 mM Tris-HCl (pH 7.5) containing 100 mM dithiothreitol and 0.1 mM ATP. The isolated nuclei were incubated with preactivated PTX (20 µg/ml) at 25 °C for 20 min in buffer A containing 1 mM NAD and 50 µM GDP. The treated nuclei were washed with buffer A and then the effects of prostaglandin analogs on intranuclear calcium levels were measured by fura-2/AM fluorometry as above.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

[3H]PGE2 Binding to Subcellular Fractions-- The maximal specific binding of [3H]PGE2 to newborn pig brain plasma membrane, ER, and nuclear membrane fractions was comparable (Table I); in adult rat liver, the Bmax for [3H]PGE2 on plasma and nuclear membranes was also similar. The affinity constant (KD) of PGE2 binding did not significantly differ between tissues and membrane fractions. Subtypes of PGE2 receptors were studied by displacement of bound [3H]PGE2 with PGE2, AH6809 (EP1 receptor antagonist), butaprost (EP2 agonist), M&B 28,767 (EP3 subtype agonist), and AH23848B (EP4 antagonist) (6). Neonatal porcine brain plasma and nuclear membranes contained mostly EP3 receptors (nearly 100 and 45%, respectively); on nuclear membranes, the balance of EP receptors was equally divided among EP1, EP2, and EP4 (Fig. 1, a and b). In adult liver plasma membranes, all four EP receptors were detected in equal proportions (25%); in liver nuclear membranes, EP3 was most abundant (40%), and EP1, EP2, and EP4 consisted 15, 20, and 30% of EP receptors, respectively (Fig. 1, c and d). [3H]PGE2 displacement data and the availability of specific anti-EP3alpha and anti-EP4 receptor antibodies (29) led us to focus our investigation on the cellular localization of EP3alpha and EP4 receptors, and the remaining studies concentrated on these two receptor subtypes.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Maximum specific binding of [3H]PGE2 (Bmax) on cell fractions
Values (Bmax in fmol/mg protein, KD in nM) are mean ± S.E. of three experiments, in duplicate. ND, not determined.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Competitive displacement of [3H]PGE2 binding to plasma and nuclear membrane from newborn pig brain and adult rat liver by prostaglandins and analogs. Shown are brain plasma membrane (a), nuclear membrane (b), liver plasma membrane (c), and nuclear membrane (d). Membranes were incubated with 10 nM [3H]PGE2 at 37 °C for 30 min in the presence or absence of 25 µM unlabeled PGE2 to determine 100% specific binding. black-square, PGE2; triangle , AH6809 (EP1 antagonist); black-diamond , butaprost (EP2 agonist); open circle , M&B 28,767 (EP3 agonist); black-down-triangle , AH2384B (EP4 antagonist). Each data point is the mean ± S.E. of four experiments performed in duplicate.

Expression of EP3alpha and EP4 Immunoreactive Protein in Newborn Brain Subcellular Fractions-- Immunoblot analysis revealed immunoreactive bands in plasma and nuclear fractions of similar molecular masses (EP3alpha , 60 kDa; EP4, 63 kDa) (Fig. 2).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 2.   Immunoblot of EP3alpha and EP4 receptor proteins (see arrows) in plasma membrane (P) and nuclear membrane (N) fractions from newborn pig brain. Top and bottom arrows point to EP4 and EP3alpha bands, respectively; only one band was detected in the range of interest (50-65 kDa).

Indirect Immunofluorescence of EP3alpha and EP4 Receptors in Porcine Cerebral Vessel Endothelial Cells-- Because cerebral microvessels contain a number of high affinity PGE2 binding sites (20), primary cultures of newborn pig brain microvascular endothelial cells were used to study the intracellular distribution of EP3alpha and EP4 receptors by confocal microscopy. No fluorescence was detected in the absence of the primary antibodies (Fig. 3a). Immunoreactivity for both receptor subtypes was detected in the plasma membrane (Figs. 3b and 4a), in the cytoplasm, and at the nucleus (Figs. 3c and 4b). EP3alpha specific fluorescence in the nuclear envelope appeared as a perinuclear halo (Fig. 3c); the latter was more prominent than that of EP4 receptors (Fig. 4b). The cells were stained with DiOC6 (3) to identify intracellular membranes, mainly ER (Figs. 3d and 4c). Merging the images from EP3alpha or EP4 specific red immunofluorescence with DiOC6 (3) green staining revealed that EP receptors colocalized on intracellular membranes as indicated by the bright yellow-orange fluorescence (Fig. 3e and 4d); however, the stains did not fully converge, suggesting distinct sites particularly evident in the perinuclear region. Cells were also stained with a nuclear stain, Sytox Green (Fig. 3g). A transverse section (Z-section) of this image superimposed with that of the EP3alpha immunoreative staining (Fig. 3h) in the same cell revealed that the immunoreactivity was perinuclear and not intranuclear (Fig. 3i); similar results were obtained using the EP4 antibody (data not shown). No immunofluorescence was detected when the antibodies were preincubated with their cognate peptides (Figs. 3f and 4e). EP3alpha and EP4 immunoreactivity in co-localization with DiOC6 (3) staining apparently in the nucleoli of a few endothelial cells (Figs. 3, c-e and 4, b-d) was not consistently observed (Fig. 3h) and remains unexplained at this point.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Confocal microscopy of porcine cerebral microvascular endothelial cells immunofluorescently stained for EP3alpha receptors. Cells were subjected to indirect immunofluorescent staining using affinity purified rabbit anti-peptide EP3alpha antibodies followed by Texas Red-conjugated anti-rabbit IgG. a, Texas Red-conjugated IgG alone; note absence of immunofluorescence. EP3alpha immunoreactivity on plasma membrane (b) and nuclear membrane and cytoplasm (c); note perinuclear halo in more extensively permeabilized cells (see "Experimental Procedures"). d, DiOC6 (3), intracellular membranes (mostly endoplasmic reticulum) stain; e, superimposed images of panels c and d; note red (EP3alpha immunoreactivity) perinuclear halo. f, anti-EP3alpha in the presence of cognate peptide, (10 µg/ml), note lack of immunofluorescence; g, Sytox Green nucleus stain; h, EP3alpha immunoreactivity; i, Z section of superimposed images of panels g and h.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Confocal microscopy of porcine cerebral microvascular endothelial cells immunofluorescently stained for EP4 receptors. Cells were subjected to indirect immunofluorescent staining using affinity purified rabbit anti-peptide EP4 antibodies followed by Texas Red-conjugated anti-rabbit IgG. EP4 immunoreactivity on plasma membrane (a), and nuclear membrane and cytoplasm (b); perinuclear halo is noted in more extensively permeabilized cells (see "Experimental Procedures"). c, DiOC6 (3), intracellular membranes (mostly endoplasmic reticulum) stain; d, superimposed images of panels b and c, note red (EP4 immunoreactivity) perinuclear halo; e, anti-EP4 in the presence of cognate peptide (10 µg/ml), note absent immunofluorescence.

Indirect Immunofluorescence of EP3alpha and EP4 Receptors in HEK 293 Cells-- To assess whether this perinuclear distribution of EP3alpha and EP4 receptors applies generally to cells, the localization of these receptors was studied after transfection of cDNA for EP3alpha and EP4 into HEK 293 cells that do not normally express prostanoid receptors (39); ectopically expressed EP receptors in HEK 293 cells bind PGE2 and are functional (39, 40). Immunoreactivity for EP3alpha and EP4 receptors was seen on the plasma membrane (Fig. 5, c and g) and perinuclear area, which are in proximity to each other in the transfected HEK 293 cells (Fig. 5d, h), which are relatively small and contain limited cytoplasm compared with endothelial cells. As expected, no immunofluorescence was detected in the wild-type cells (Fig. 5a) or after preincubation of the antibodies with their cognate peptide epitopes (Fig. 5 f and j).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   EP3alpha and EP4 immunofluorescent staining of overexpressing clones of human EP3alpha or human EP4 receptors in HEK 293 cells. a, cells transfected with vector alone, note absence of immunofluorescence; b, nuclear stain (DAPI) of cells from panel a. EP3alpha immunoreactivity on plasma membrane (c) and nuclear membrane (d); note the perinuclear halo in more permeabilized cells (see "Experimental Procedures"). e, nuclear stain (DAPI) of cells from panel d. f, anti-EP3alpha in the presence of cognate peptide (10 µg/ml), note the lack of immunofluorescence. EP4 immunoreactivity on plasma membrane (g) and nuclear membrane (h), note the perinuclear halo in more permeabilized cells (see "Experimental Procedures"). i, nuclear stain (DAPI) of cells from panel h; j, anti-EP4 in the presence of cognate peptide (10 µg/ml).

Immunogold Labeling of EP3alpha and EP4 Receptors-- Thus far, indirect immunofluorescence studies revealed a perinuclear localization of EP3alpha and EP4 receptors. To distinguish the nuclear envelope, immunoelectron microscopy of porcine cerebrovascular endothelial cells was performed and confirmed that EP3alpha and EP4 immunoreactivity was indeed at the nuclear envelope (Fig. 6, c and f). As expected, these receptors were detected on plasma membranes (Fig. 6 b and e) and Golgi vesicles (Fig. 6d). No immunogold staining was observed in the absence of the primary antibodies (Fig. 6a) or in the nucleoli of cells (data not shown). EP3alpha and EP4 nuclear envelope immunogold staining was detected in the majority of cells observed (95% of cells, over 100 cells observed in each case).


View larger version (193K):
[in this window]
[in a new window]
 
Fig. 6.   Immunogold localization of EP3alpha and EP4 receptors in porcine cerebrovascular endothelial cells by electron microscopy (see arrows). a, anti-rabbit gold-conjugated IgG alone; note absence of immunostaining when primary antibody is omitted. EP3alpha immunoreactivity on plasma membrane (b) and nuclear membrane (c). EP4 immunoreactivity on Golgi vesicles (d), plasma membrane (e), and nuclear membrane (f). Scale bar in each represents 0.5 µm.

Effects of Stimulation of Porcine Cerebrovascular Endothelial Cells Nuclear EP Receptors on iNOS Gene Transcription-- Recent studies have shown that endogenous PGE2 has a stimulatory effect on inducible nitric-oxide synthase (iNOS) (41, 42). We tested whether the stimulation of nuclear EP receptors by prostaglandin analogs may affect iNOS transcription, as determined by dot hybridization of RNA studies. Stimulation of intact nuclei isolated from primary cultures of porcine brain endothelial cells with EP3 receptor agonist M&B 28,767 (0.1 µM) increased transcription of iNOS (Fig. 7a) to a greater extent than after stimulation of whole cells.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of nuclear EP receptor stimulation on iNOS gene transcription and nuclear calcium transients. a, effects of EP3 agonist M&B 28,767 (0.1 µM) on iNOS transcription in neonatal porcine cerebral microvascular endothelial cells (primary culture from newborn brain) as determined by dot blot hybridization of RNA; MB and C refer to M&B 28,767 and control (unstimulated), respectively. beta -Actin dot blot indicates equal loading. One representative dot blot of three is shown. b, effect of M&B 28,767 (1 µM) on 45Ca2+ uptake by isolated liver nuclei; control refers to absence of drug. The free calcium concentration was 400 nM. The movement of 45Ca2+ transient after a given time was defined as radioactivity at a given time minus the radioactivity at time 0. c, typical tracings showing effects of PGE2 analog 16,16-dimethyl PGE2 (1 µM) and EP3 agonist M&B 28,767 (0.01-1 µM) on intranuclear calcium concentrations ([Ca2+]n) in isolated liver nuclei loaded with fura-2/AM; arrow shows the time of application of test agents. d, peak increases in isolated liver intranuclear calcium ([Ca2+]n) after addition of M&B 28,767 (1 µM) in the presence or absence of PTX preincubation (20 µg/ml, 20 min at 25 °C). Experiments (b-d) were carried out on three independent isolations of intact nuclei, each one performed in duplicate.

Effects of Stimulation of Rat Liver Nuclear EP Receptors on Ca2+ Transients-- The nuclear envelope contains distinct nuclear calcium pools that play crucial roles in major nuclear functions including gene transcription (13). The amplitude and duration of calcium signals have been shown to control differential activation of transcription factors (43). In addition, Ca2+ can activate iNOS independent of protein kinases C and A (44). We tested whether stimulation of nuclear EP3 receptors with prostaglandin analogs could affect calcium concentrations in isolated nuclei of liver; stimulation of EP4 receptors could not be performed because of lack of availability of specific agonists. Application of M&B 28,767 (1 µM, an EP3-selective agonist) to intact isolated nuclei caused rapid nuclear uptake of 45Ca2+ (Fig. 7b). In addition, this EP3 agonist produced a dose-dependent increase in rat liver nuclear calcium as determined by fura-2/AM, a fluorescent dye which localizes in the nuclear envelope space (45) (Fig. 7c); M&B 28,767 (1 µM) was nearly as effective as the nonselective EP agonist 16,16-dimethyl PGE2 (1 µM).

We determined whether the nuclear calcium uptake evoked by the EP3 agonist M&B 28,767 was dependent on G proteins. EP3 couples to Gi or Go (46), which are known to affect Ca2+ mobilization (46, 47); such G proteins are detected in rat liver nuclei (38). Because PTX causes these G proteins to lose their ability to associate with receptors, we tested the effects of PTX on M&B 28,767-induced Ca2+ transients. Pretreatment of isolated nuclei with PTX markedly attenuated the stimulatory effect of M&B 28,767 (1 µM) on intranuclear calcium levels, suggesting the involvement of a PTX-sensitive G protein in mediating the effects of nuclear EP3 receptors (Fig. 7d). In contrast, M&B 28,767 did not inhibit forskolin-stimulated cAMP formation (data not shown). These findings are consistent with coupling of nuclear EP3 receptors to G proteins which may directly control Ca2+ channels independently of second messengers, as mostly reported for Gi (47, 48).

In conclusion, the data presented provides the first clear evidence for the presence of the G protein-coupled receptors, EP3alpha and EP4 at nuclear membranes of native tissues as well as primary and transfected cells. Furthermore, these receptors seem to be functional as revealed by increased iNOS transcription and nuclear calcium by EP3 agonist, M&B 28,767, which also appears to involve PTX-sensitive G proteins. The plasma and nuclear membrane EP3alpha as well as EP4 receptors appear to be related because they had similar molecular weights, binding kinetics, ligand binding properties, and immunoreactivity. Also, the comparable distribution of ectopically expressed EP3alpha and EP4 receptors in HEK 293 cells suggested that the plasma and nuclear membrane EP receptors may be alike. Radioligand binding studies have identified the presence of two other classes of G protein-coupled receptors at the nuclear membrane, the muscarinic acetylcholine (49) and angiotensin II receptors, AT1 (23); but the AT1 receptor can be detected in the nucleus only after stimulation by angiotensin II (50). Other prostanoids, namely PGD2, its metabolite PGJ2, and PGI2 can activate the peroxisome proliferator-activated receptors (PPARs) that are members of the nuclear receptor superfamily, but PPARs are not responsive to PGE2 (51, 52). However, the presence of EP1 receptors at the nuclear membranes has recently been suggested (19) albeit its mechanism of action is not clear.

In the newborn brain and cerebral microvasculature, PGE2 receptors and associated functions at the plasma membrane are down-regulated (2, 20). On the other hand, PGE2 plays a role in neuroprotection by acting on EP2 and perhaps EP4 (53). PGE2 also increases the expression of nitric-oxide synthase via stimulation of EP3 receptors in the neonate (54). In addition, the perinuclear cyclooxygenase-1 and -2 (7) can produce prostanoids that can act at the nuclear level (11, 12) and modulate transcription of genes, as had been speculated for iNOS (41). The present discovery of nuclear EP3 and EP4 receptors proposes new avenues for the intracellular actions of prostanoids, which may also explain certain effects of PGE2 especially when plasma membrane EP receptors are barely detectable. Further studies are needed to clarify the detailed signal transduction mechanisms involved in this action of prostaglandins via nuclear EP receptors.

    ACKNOWLEDGEMENTS

We thank Hensy Fernandez and Marie Ballak for technical assistance.

    FOOTNOTES

* This work was supported by the Medical Research Council of Canada and the Fonds de la Recherche en Santé du Québec.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a Doctoral Research Award from the Medical Research Council of Canada.

Dagger Dagger To whom correspondence should be addressed: Research Center of Hôpital Ste. Justine, 3175-Côte Sainte-Catherine, Montreal, Quebec H3T 1C5 Canada. Tel.: 514-345-4692; Fax: 514-345-4801; E-mail: chemtobs{at}ere.umontreal.ca.

    ABBREVIATIONS

The abbreviations used are: PGE2, prostaglandin E2; EP, PGE2 receptor; NEST, nuclear envelope signal transduction; HEK, human embryonic kidney cells; ER, endoplasmic reticulum; PBS, phosphate-buffered saline; iNOS, inducible nitric-oxide synthase; PTX, pertussis toxin; DiOC6, 3,3'-dihexyloxacarbocyanine iodide; DAPI, 4'-6-diamino-2-phenylindole.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
  1. Leffler, C., and Busija, D. (1985) Prostaglandins 30, 811-817[CrossRef][Medline] [Order article via Infotrieve]
  2. Chemtob, S., Li, D. Y., Abran, D., Hardy, P., Peri, K., and Varma, D. (1996) Acta Paediatrica. 85, 517-524[Medline] [Order article via Infotrieve]
  3. Baylink, T. M., Mohan, S., Fitzsimmons, R. J., and Baylink, D. J. (1996) J. Bone Miner. Res. 11, 1413-1418[Medline] [Order article via Infotrieve]
  4. Yano, T., Tano, Y., Uchida, M., Murakami, A., Hagiwara, K., Otani, S., and Ichikawa, T. (1997) Biochem. Pharmacol. 53, 1757-1759[CrossRef][Medline] [Order article via Infotrieve]
  5. Simonson, M. S., Herman, W. H., and Dunn, M. J. (1994) Exp. Cell Res. 215, 137-144[CrossRef][Medline] [Order article via Infotrieve]
  6. Coleman, R. A., Smith, W. L., and Narumiya, S. (1994) Pharmacol. Rev. 46, 205-229[Medline] [Order article via Infotrieve]
  7. Spencer, A., Woods, J., Arakawa, T., Singer, I., and Smith, W. L. (1998) J. Biol. Chem. 273, 9886-9893[Abstract/Free Full Text]
  8. Kanai, N., Run, L., Satriano, J., Yi, B., Wolkoff, A., and Schuster, V. (1995) Science 268, 866-869[Medline] [Order article via Infotrieve]
  9. Schievella, A., Regier, M., Smith, W., and Lin, L-L. (1995) J. Biol. Chem. 270, 30749-30754[Abstract/Free Full Text]
  10. Coffey, R. J., Hawkey, C. J., Damstrup, L., Graves-Deal, R., Daniel, V. C., Dempsey, P. J., Chinery, R., Kirkland, S., DuBois, R., Jetton, T., and Morrow, J. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 657-662[Abstract/Free Full Text]
  11. Goetzl, E., An, S., and Smith, W. (1995) FASEB J. 9, 1051-1058[Abstract/Free Full Text]
  12. Morita, I., Schindler, M., Regier, M., Otto, J. C., Hori, T., DeWitt, D., and Smith, W. (1995) J. Biol. Chem. 270, 10902-10908[Abstract/Free Full Text]
  13. Malviya, A., and Rogue, P. (1998) Cell 92, 17-23[Medline] [Order article via Infotrieve]
  14. Nicotera, P., McConkey, D., Jones, D., and Orrenius, S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 453-457[Abstract]
  15. Baldassare, J. J, Jarpe, M., Alferes, L., and Raben, D. M. (1997) J. Biol. Chem. 272, 4911-4914[Abstract/Free Full Text]
  16. Saffitz, J., Nash, J., Green, K., Luke, R., Ransnas, L., and Insel, P. (1994) FASEB J. 8, 252-258[Abstract/Free Full Text]
  17. Lepretre, N., Mironneau, J., and Morel, J. L. (1994) J. Biol. Chem. 269, 29546-29552[Abstract/Free Full Text]
  18. Divencha, N., Banfic, H., and Irvine, R. F. (1993) Cell 74, 405-407[Medline] [Order article via Infotrieve]
  19. Bhattacharya, M., Peri, K., Almazan, G., Ribeiro-da-Silva, A., Shichi, S., Durocher, D., Abramovitz, M., Hou, X., Varma, D., and Chemtob, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15792-15797[Abstract/Free Full Text]
  20. Li, D. Y., Varma, D., and Chemtob, S. (1994) Br. J. Pharmacol. 112, 59-64[Abstract]
  21. Virgolini, I., Muller, C., Herman, M., Schutz, W., and Sinzinger, H. (1988) Prostaglandins 36, 807-818[Medline] [Order article via Infotrieve]
  22. Lahaie, I., Hardy, P., Hou, X., Hassessian, H., Asselin, P., Lachapelle, P., Almazan, G., Varma, D., Morrow, J., Jackson Roberts, L., and Chemtob, S. (1998) Am. J. Physiol. 274, 1406-1416
  23. Booz, G., Conra, K., Hess, A., Singer, H., and Baker, K. (1992) Endocrinology 130, 3641-3649[Abstract]
  24. Rubin, B., Fox, T., and Bridges, R. (1986) Brain Res. 383, 60-67[CrossRef][Medline] [Order article via Infotrieve]
  25. Croze, E. M., and Morre, D. J. (1984) J. Cell. Physiol. 119, 46-57[Medline] [Order article via Infotrieve]
  26. Noordlie, R., and Arion, W. (1966) Methods Enzymol. 9, 619-625[CrossRef]
  27. Dale, B., DeFelice, L., Kyozuka, K., Santella, L., and Tosti, E. (1994) Proc. R. Soc. Lond. Ser. B Biol. Sci. 255, 119-124
  28. Peri, K., Hardy, P., Li, D. Y., Varma, D., and Chemtob, S. (1995) J. Biol. Chem. 270, 24615-24620[Abstract/Free Full Text]
  29. Zhao, C., Fujimoto, N., and Shichi, H. (1995) J. Ocul. Pharmacol. Ther. 11, 421-435[Medline] [Order article via Infotrieve]
  30. Adam, M., Boie, Y., Rushmore, T., Muller, G., Bastien, L., McKee, K., Metters, K., and Abramovitz, M. (1994) FEBS Lett. 338, 170-174[CrossRef][Medline] [Order article via Infotrieve]
  31. Bastien, L., Sawyer, N., Grygorczyk, R., Metters, K., and Adam, M. (1994) J. Biol. Chem. 269, 11873-11877[Abstract/Free Full Text]
  32. Figueiredo, B. C., Almazan, G., Ma, Y., Tetzlaff, W., Miller, F., and Cuello, A. (1993) Mol. Brain Res. 17, 258-268[Medline] [Order article via Infotrieve]
  33. Pickel, V., Chan, J., and Aoki, C. (1993) in Immunohistochemistry (Cuello, A., ed), John Wiley & Sons, Chichester, UK
  34. Ribeiro-da-Silva, A., Priestly, J., and Cuello, A. (1993) Immunohistochemistry, John Wiley & Sons, Chichester, UK
  35. Greenberg, M., and Ziff, E. (1984) Nature 311, 433-437[Medline] [Order article via Infotrieve]
  36. Sambrook, J., Fritsch, E., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  37. Adachi, H., Iida, S., Oguchi, S., Ohsima, H., Suzuki, H., Nagasaki, K., Kawasaki, H., Sugimura, T., and Esumi, H. (1993) Eur. J. Biochem. 217, 37-43[Abstract]
  38. Takei, Y., Takahashi, K., Kanaho, Y., and Katada, T. (1994) J. Biochem. 115, 578-583[Abstract]
  39. Boie, Y., Stocco, R., Sawyer, N., Slipetz, D., Ungrin, M., Neuschafer-Rube, F., Puschel, G., Metters, K., and Abramovitz, M. (1997) Eur. J. Pharmacol. 340, 227-241[CrossRef][Medline] [Order article via Infotrieve]
  40. Neuschafer-Rube, F., Hanecke, K., Blaschke, V., Jungermann, K., and Puschel, G. (1997) FEBS Lett. 401, 185-190[CrossRef][Medline] [Order article via Infotrieve]
  41. Minghetti, L., Nicolini, A., Polazzi, E., Creminon, C., Maclouf, J., and Levi, G. (1997) Glia 19, 152-160[CrossRef][Medline] [Order article via Infotrieve]
  42. Di Rosa, M., Lalenti, A., and Lanaro, A. (1996) Prostaglandins Leukotrienes Essent. Fatty Acids 54, 229-238[Medline] [Order article via Infotrieve]
  43. Dolmetsch, R. E., Lewis, R. S., Goodnow, C. C., and Healy, J. I. (1997) Nature 386, 855-858[CrossRef][Medline] [Order article via Infotrieve]
  44. Takagi, H., Toda, N., and Hawkins, R. D. (1994) Nitric Oxide: Roles in Neuronal Communication and Neurotoxicity, p. 44, Japan Scientific Societies Press, CRC Press, Tokyo
  45. Gerasimenko, O. V., Gerasimenko, J. V., Tepikin, A. V., and Petersen, O. H. (1996) Eur. J. Physiol. 432, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  46. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., and Narumiya, S. (1993) Nature 365, 166-170[CrossRef][Medline] [Order article via Infotrieve]
  47. Barsony, J., and Marx, S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1188-1192[Abstract]
  48. Hescheler, J., Rosenthal, W., Hinsch, K. D., Wulfern, M., Trautwein, W., and Schultz, G. (1988) EMBO J. 7, 613-624
  49. Lind, G., and Cavanagh, H. (1993) Invest. Ophthalmol. Visual Sci. 34, 2943-2952[Abstract]
  50. Lu, D., Yang, H., Shaw, G., and Raizada, M. (1998) Endocrinology 139, 365-375[Abstract/Free Full Text]
  51. Kliewer, S., Lenhard, J., Willson, T., Patel, I., Morris, D., and Lehmann, J. (1995) Cell 83, 813-819[Medline] [Order article via Infotrieve]
  52. Hertz, R., Berman, I., Keppler, D., and Bar-Tana, J. (1996) Eur. J. Biochem. 235, 242-247[Abstract]
  53. Doke, A., Hardy, P., Peri, K., Molotchnikoff, S., Varma, D., Lachapelle, P., Roy, M-S., and Chemtob, S. (1996) Pediatr. Res. 39, 205A
  54. Dumont, I., Peri, K., Abran, D., Hardy, P., Molotchnikoff, S., Varma, D., and Chemtob, S. (1998) Am. J. Physiol. 275, R1812-R1821[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.